Pfizer Chantix Review Shows Pitfalls Of Patient-Reported Outcomes
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The debate over analysis of clinical trial endpoints in FDA review documents for Pfizer’s Chantix (varenicline) provides a window into how the agency’s view of smoking cessation trial design is changing as new therapeutic classes emerge.
You may also be interested in...
Pharmacometric Reviews Increasingly Influence FDA Regulatory Decisions
Drug makers should routinely perform exposure-response analyses across Phase II and III studies to find consistencies across trials, FDA said in a recent survey of 31 NDAs submitted between 2005 and 2006.
Pharmacometric Reviews Increasingly Influence FDA Regulatory Decisions
Drug makers should routinely perform exposure-response analyses across Phase II and III studies to find consistencies across trials, FDA said in a recent survey of 31 NDAs submitted between 2005 and 2006.
Pfizer Challenge To Lyrica Abuse Liability Assessment Delayed Approval
Pfizer removed the final hurdle to approval of Lyrica (pregabalin) when it relented in its opposition to FDA's assessment of the potential for abuse of the drug, agency review documents show